| Melissa Geason, | |
|
514 Riverview Ave, Waukesha, WI 53188-3631 | |
| (262) 548-7666 | |
| (262) 970-6696 |
| Full Name | Melissa Geason |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 26 Years |
| Location | 514 Riverview Ave, Waukesha, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821452095 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 7247 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cornerstone Counseling Services Inc | 1456256023 | 92 |
News Archive
Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
McKesson Corporation, the nation's oldest and largest healthcare services and IT company, today announced the release of its 2008-2009 Corporate Citizenship Report and launched the McKesson Foundation's new strategic focus on chronic disease management.
A new Commonwealth Fund report shows that women in the United States are in much worse shape, health care-wise, than women in 10 nations that have universal health care. Even insured American women are more likely to go without needed health care because of the cost and difficulty paying medical bills. The report was published online July 13. According to the report, the Affordable Care Act has brought coverage to millions of women already and is expected to improve women's health care in coming years.
New research suggests that looking at structures in the right side of the brain may help predict who will better recover from language problems after a stroke, according to a study published in Neurology, a medical journal of the American Academy of Neurology.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
› Verified 7 days ago
| Entity Name | Cornerstone Counseling Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033127246 PECOS PAC ID: 1456256023 Enrollment ID: O20031205000446 |
News Archive
Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
McKesson Corporation, the nation's oldest and largest healthcare services and IT company, today announced the release of its 2008-2009 Corporate Citizenship Report and launched the McKesson Foundation's new strategic focus on chronic disease management.
A new Commonwealth Fund report shows that women in the United States are in much worse shape, health care-wise, than women in 10 nations that have universal health care. Even insured American women are more likely to go without needed health care because of the cost and difficulty paying medical bills. The report was published online July 13. According to the report, the Affordable Care Act has brought coverage to millions of women already and is expected to improve women's health care in coming years.
New research suggests that looking at structures in the right side of the brain may help predict who will better recover from language problems after a stroke, according to a study published in Neurology, a medical journal of the American Academy of Neurology.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
› Verified 7 days ago
| Entity Name | County Of Waukesha Department Of Finance |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740403146 PECOS PAC ID: 3971405481 Enrollment ID: O20040124000130 |
News Archive
Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
McKesson Corporation, the nation's oldest and largest healthcare services and IT company, today announced the release of its 2008-2009 Corporate Citizenship Report and launched the McKesson Foundation's new strategic focus on chronic disease management.
A new Commonwealth Fund report shows that women in the United States are in much worse shape, health care-wise, than women in 10 nations that have universal health care. Even insured American women are more likely to go without needed health care because of the cost and difficulty paying medical bills. The report was published online July 13. According to the report, the Affordable Care Act has brought coverage to millions of women already and is expected to improve women's health care in coming years.
New research suggests that looking at structures in the right side of the brain may help predict who will better recover from language problems after a stroke, according to a study published in Neurology, a medical journal of the American Academy of Neurology.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
› Verified 7 days ago
| Entity Name | Affiliated Clinical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851473698 PECOS PAC ID: 0244124899 Enrollment ID: O20040212000835 |
News Archive
Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
McKesson Corporation, the nation's oldest and largest healthcare services and IT company, today announced the release of its 2008-2009 Corporate Citizenship Report and launched the McKesson Foundation's new strategic focus on chronic disease management.
A new Commonwealth Fund report shows that women in the United States are in much worse shape, health care-wise, than women in 10 nations that have universal health care. Even insured American women are more likely to go without needed health care because of the cost and difficulty paying medical bills. The report was published online July 13. According to the report, the Affordable Care Act has brought coverage to millions of women already and is expected to improve women's health care in coming years.
New research suggests that looking at structures in the right side of the brain may help predict who will better recover from language problems after a stroke, according to a study published in Neurology, a medical journal of the American Academy of Neurology.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Geason, 514 Riverview Ave, Waukesha, WI 53188-3631 Ph: (262) 548-7666 | Melissa Geason, 514 Riverview Ave, Waukesha, WI 53188-3631 Ph: (262) 548-7666 |
News Archive
Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
McKesson Corporation, the nation's oldest and largest healthcare services and IT company, today announced the release of its 2008-2009 Corporate Citizenship Report and launched the McKesson Foundation's new strategic focus on chronic disease management.
A new Commonwealth Fund report shows that women in the United States are in much worse shape, health care-wise, than women in 10 nations that have universal health care. Even insured American women are more likely to go without needed health care because of the cost and difficulty paying medical bills. The report was published online July 13. According to the report, the Affordable Care Act has brought coverage to millions of women already and is expected to improve women's health care in coming years.
New research suggests that looking at structures in the right side of the brain may help predict who will better recover from language problems after a stroke, according to a study published in Neurology, a medical journal of the American Academy of Neurology.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
› Verified 7 days ago
Ms. Natasha Jean Pinkerton, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 725 American Ave, Waukesha, WI 53188 Phone: 262-928-1000 | |
Mr. Jerome Michael Loberg, M.S.W. Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1501 Airport Rd., Waukesha, WI 53188 Phone: 262-548-7930 | |
Cindy M Sywyk, MSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 721 American Ave, Suite 501, Waukesha, WI 53188 Phone: 262-928-2396 Fax: 262-544-1213 | |
Gary Swan, MSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 2607 N Grandview Blvd, Suite 104, Waukesha, WI 53188 Phone: 262-446-9981 Fax: 262-446-9983 | |
Robert K Porter, MSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 721 American Ave, Suite 501, Waukesha, WI 53188 Phone: 262-928-2396 Fax: 262-544-1213 | |
Susan L Driscoll, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1501 Airport Rd, Waukesha, WI 53188 Phone: 262-548-7950 | |
Marilyn Tauscher, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 721 American Ave, Ste 501, Waukesha, WI 53188 Phone: 262-928-4036 |